Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription

Articles published in Eur J Cancer

Retrieve available abstracts of 93 articles:
HTML format

Single Articles

    March 2023
  1. SCHMIDT MK, Kelly JE, Bredart A, Cameron DA, et al
    EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
    Eur J Cancer. 2023;181:79-91.
    PubMed     Abstract available

    February 2023
  2. WANG J, Cai L, Song Y, Sun T, et al
    Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).
    Eur J Cancer. 2023;184:73-82.
    PubMed     Abstract available

  3. ROBSON ME, Im SA, Senkus E, Xu B, et al
    OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Eur J Cancer. 2023;184:39-47.
    PubMed     Abstract available

  4. HOLMES FA, Moy B, Delaloge S, Chia SKL, et al
    Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
    Eur J Cancer. 2023;184:48-59.
    PubMed     Abstract available

    January 2023
  5. FASCHING PA, Hein A, Kolberg HC, Haberle L, et al
    Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
    Eur J Cancer. 2023;184:1-9.
    PubMed     Abstract available

    December 2022
  6. YANG F, Liu G, Mao F, Zheng YC, et al
    Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer.
    Eur J Cancer. 2022 Dec 27:S0959-8049(22)01763-4. doi: 10.1016/j.ejca.2022.

  7. NUCIFORO P, Townend J, Piccart MJ, Fielding S, et al
    Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
    Eur J Cancer. 2022;181:92-101.
    PubMed     Abstract available

  8. KANG S, Kim SB
    Response to letter to the editor re: Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
    Eur J Cancer. 2022 Dec 16:S0959-8049(22)01764-6. doi: 10.1016/j.ejca.2022.

  9. BELTRAN-BLESS AA, Clemons MJ, Fesl C, Greil R, et al
    Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.
    Eur J Cancer. 2022;180:108-116.
    PubMed     Abstract available

  10. CABASAG CJ, Vignat J, Ferlay J, Arndt V, et al
    The preventability of cancer in Europe: A quantitative assessment of avoidable cancer cases across 17 cancer sites and 38 countries in 2020.
    Eur J Cancer. 2022;177:15-24.
    PubMed     Abstract available

    November 2022
  11. BRAVACCINI S, Puccetti M, Maltoni R
    Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer".
    Eur J Cancer. 2022 Nov 13. pii: S0959-8049(22)00801.

  12. JIAO Y, Truong T, Eon-Marchais S, Mebirouk N, et al
    Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
    Eur J Cancer. 2022;179:76-86.
    PubMed     Abstract available

  13. TARANTINO P, Nicolo E, Curigliano G
    Response to letter entitled: Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer".
    Eur J Cancer. 2022 Nov 9. pii: S0959-8049(22)00802.

    October 2022
  14. LOIBL S, Loirat D, Tolaney SM, Punie K, et al
    Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
    Eur J Cancer. 2022;178:23-33.
    PubMed     Abstract available

  15. VAN DAM P, Tomatis M, Ponti A, Marotti L, et al
    The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres.
    Eur J Cancer. 2022;177:72-79.
    PubMed     Abstract available

  16. GHANNAM Y, Di Meglio A, Sarrade T, Jacquet A, et al
    Impact of radiation therapy on fatigue at 1 year in breast cancer survivors in the prospective multicentre CANcer TOxicity cohort.
    Eur J Cancer. 2022;177:143-153.
    PubMed     Abstract available

  17. SWAIN SM, Tan AR, Gianni L, Kuemmel S, et al
    Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
    Eur J Cancer. 2022;178:70-81.
    PubMed     Abstract available

  18. HUANG M, O'Shaughnessy J, Haiderali A, Pan W, et al
    Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1.
    Eur J Cancer. 2022;177:45-52.
    PubMed     Abstract available

  19. TARANTINO P, Niman SM, Erick TK, Priedigkeit N, et al
    HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.
    Eur J Cancer. 2022;174:277-286.
    PubMed     Abstract available

  20. VILLACAMPA G, Falato C, Pare L, Hernando C, et al
    Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
    Eur J Cancer. 2022;174:232-242.
    PubMed     Abstract available

  21. M A, S C, J F, C L, et al
    Incidence and Outcome of Breast Sarcomas in England (2013-2018): An analysis from the National Cancer Registration and Analysis Service.
    Eur J Cancer. 2022;174:48-56.
    PubMed     Abstract available

  22. HOUVENAEGHEL G, de Nonneville A, Cohen M, Classe JM, et al
    Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study.
    Eur J Cancer. 2022;176:58-69.
    PubMed     Abstract available

    September 2022
  23. KANG S, Lee SH, Lee HJ, Jeong H, et al
    Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
    Eur J Cancer. 2022;176:30-40.
    PubMed     Abstract available

  24. JIANG H, Ouyang Q, Yin Y, Tong Z, et al
    Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis.
    Eur J Cancer. 2022;176:1-12.
    PubMed     Abstract available

  25. PFOB A, Sidey-Gibbons C, Barr RG, Duda V, et al
    Intelligent multi-modal shear wave elastography to reduce unnecessary biopsies in breast cancer diagnosis (INSPiRED 002): a retrospective, international, multicentre analysis.
    Eur J Cancer. 2022;177:1-14.
    PubMed     Abstract available

  26. XU B, Hu X, Li W, Sun T, et al
    Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.
    Eur J Cancer. 2022;175:236-245.
    PubMed     Abstract available

  27. BAEZ-NAVARRO X, Salgado R, Denkert C, Lennerz JK, et al
    Selecting patients with HER2-low breast cancer: Getting out of the tangle.
    Eur J Cancer. 2022;175:187-192.
    PubMed     Abstract available

  28. VLIEK SB, Hilbers FS, Jager A, Retel VP, et al
    Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.
    Eur J Cancer. 2022;175:169-179.
    PubMed     Abstract available

  29. KREGTING LM, Olthof EMG, Breekveldt ECH, Aitken CA, et al
    Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
    Eur J Cancer. 2022;175:180-186.
    PubMed     Abstract available

  30. GROOTES I, Keeman R, Blows FM, Milne RL, et al
    Incorporating progesterone receptor expression into the PREDICT breast prognostic model.
    Eur J Cancer. 2022;173:178-193.
    PubMed     Abstract available

  31. DE BOER AZ, Bastiaannet E, Schetelig J, de Glas NA, et al
    Breast cancer mortality of older patients with and without recurrence analysed by novel multi-state models.
    Eur J Cancer. 2022;174:212-220.
    PubMed     Abstract available

  32. REINERT T, Goncalves AC, de Resende CAA, Barrios CH, et al
    Implications of the PEARL trial from the low- to middle-income countries' perspectives.
    Eur J Cancer. 2022;173:30-32.

    August 2022
  33. CHEN SY, Sun GY, Tang Y, Jing H, et al
    Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial.
    Eur J Cancer. 2022;174:153-164.
    PubMed     Abstract available

  34. GOLDRAT O, De Cooman M, Mailliez A, Delbaere A, et al
    Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study.
    Eur J Cancer. 2022;174:134-141.
    PubMed     Abstract available

  35. KARSTEN MM, Roehle R, Albers S, Pross T, et al
    Corrigendum to 'Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients [European Journal of Cancer 163 (2022) 128-139].
    Eur J Cancer. 2022 Aug 12. pii: S0959-8049(22)00403.

    What a woman needs to know about overdiagnosis to decide about breast cancer screening.
    Eur J Cancer. 2022 Aug 5. pii: S0959-8049(22)00408.

    July 2022
  37. ANDERSON RA, Lambertini M, Hall PS, Wallace WH, et al
    Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy.
    Eur J Cancer. 2022;173:113-122.
    PubMed     Abstract available

  38. LEONE JP, Graham N, Tolaney SM, Leone BA, et al
    Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.
    Eur J Cancer. 2022;173:20-29.
    PubMed     Abstract available

  39. ALMSTEDT K, Heimes AS, Kappenberg F, Battista MJ, et al
    Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
    Eur J Cancer. 2022;173:10-19.
    PubMed     Abstract available

  40. DING L, Poelhekken K, Greuter MJW, Truyen I, et al
    Overdiagnosis of invasive breast cancer in population-based breast cancer screening: A short- and long-term perspective.
    Eur J Cancer. 2022;173:1-9.
    PubMed     Abstract available

  41. BUDDE A, Baust K, Weinhold L, Bernstein M, et al
    Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma.
    Eur J Cancer. 2022;170:209-235.
    PubMed     Abstract available

    June 2022
  42. BATTISTI NML, De Glas N, Soto-Perez-de-Celis E, Liposits G, et al
    Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review.
    Eur J Cancer. 2022;172:158-170.
    PubMed     Abstract available

  43. ESTEVES F, Xavier JM, Ford AM, Rocha C, et al
    Germline allelic expression of genes at 17q22 locus associates with risk of breast cancer.
    Eur J Cancer. 2022;172:146-157.
    PubMed     Abstract available

  44. BATTISTI NML, Smith IE
    Preventing late recurrence in hormone receptor-positive early breast cancer: a review.
    Eur J Cancer. 2022;172:53-64.
    PubMed     Abstract available

  45. YAMADA A, Hayashi N, Kumamaru H, Nagahashi M, et al
    Prognostic impact of postoperative radiotherapy in patients with breast cancer and with pT1-2 and 1-3 lymph node metastases: A retrospective cohort study based on the Japanese Breast Cancer Registry.
    Eur J Cancer. 2022;172:31-40.
    PubMed     Abstract available

  46. OZAKI Y, Tsurutani J, Mukohara T, Iwasa T, et al
    Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
    Eur J Cancer. 2022;171:193-202.
    PubMed     Abstract available

  47. MULLER V, Hein A, Hartkopf AD, Fasching PA, et al
    Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
    Eur J Cancer. 2022;172:13-21.
    PubMed     Abstract available

  48. ZHANG J, Gao HF, Yang C, Zhu T, et al
    Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: A phase II randomised trial.
    Eur J Cancer. 2022;171:150-160.
    PubMed     Abstract available

  49. VAN BERGE HENEGOUWEN JM, Jebbink M, Hoes LR, van der Wijngaart H, et al
    Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
    Eur J Cancer. 2022;171:114-123.
    PubMed     Abstract available

    Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study: Higher visceral tumour burden and weak estrogen rece
    Eur J Cancer. 2022;171:43.

  51. HEIMOVAARA JH, Boere IA, de Haan J, van Calsteren K, et al
    Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands.
    Eur J Cancer. 2022;171:13-21.
    PubMed     Abstract available

  52. SALGADO R, Fineberg S, De Caluwe A, de Azambuja E, et al
    Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.
    Eur J Cancer. 2022;168:138-140.

  53. SCHIZA A, Thurfjell V, Stenmark Tullberg A, Olofsson H, et al
    Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.
    Eur J Cancer. 2022;168:128-137.
    PubMed     Abstract available

    May 2022
  54. AMANT F, Nekljudova V, Maggen C, Seither F, et al
    Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
    Eur J Cancer. 2022;170:54-63.
    PubMed     Abstract available

  55. SHAGISULTANOVA E, Gao D, Callihan E, Parris HJ, et al
    Overall survival is the lowest among young women with postpartum breast cancer.
    Eur J Cancer. 2022;168:119-127.
    PubMed     Abstract available

    April 2022
  56. MASUDA N, Ono M, Mukohara T, Yasojima H, et al
    Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
    Eur J Cancer. 2022;168:108-118.
    PubMed     Abstract available

  57. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
    Eur J Cancer. 2022;168:12-24.
    PubMed     Abstract available

  58. GOKER E, Hendriks MP, van Tilburg M, Barcaru A, et al
    Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
    Eur J Cancer. 2022;167:92-102.
    PubMed     Abstract available

    March 2022
  59. DELALOGE S, Dureau S, D'Hondt V, Desmoulins I, et al
    Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.
    Eur J Cancer. 2022 Mar 22. pii: S0959-8049(22)00035.
    PubMed     Abstract available

  60. GAILLARD T, Carton M, Mailliez A, Desmoulins I, et al
    Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188].
    Eur J Cancer. 2022 Mar 18. pii: S0959-8049(22)00119.

  61. GELBER RD, Wang XV, Cole BF, Cameron D, et al
    Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY
    Eur J Cancer. 2022;166:219-228.
    PubMed     Abstract available

  62. VAN MACKELENBERGH MT, Seither F, Mobus V, O'Shaughnessy J, et al
    Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
    Eur J Cancer. 2022;166:185-201.
    PubMed     Abstract available

    February 2022
  63. LIU Z, Wang C, Chen X, Zhu J, et al
    Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
    Eur J Cancer. 2022;165:157-168.
    PubMed     Abstract available

  64. WANG Y, Reulen RC, Kremer LCM, de Vathaire F, et al
    Male breast cancer after childhood cancer: Systematic review and analyses in the PanCareSurFup cohort.
    Eur J Cancer. 2022;165:27-47.
    PubMed     Abstract available

  65. DALENC F, Lusque A, De La Motte Rouge T, Pistilli B, et al
    Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
    Eur J Cancer. 2022;164:70-79.
    PubMed     Abstract available

  66. PECE S, Sestak I, Montani F, Tillhon M, et al
    Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
    Eur J Cancer. 2022;164:52-61.
    PubMed     Abstract available

  67. MALORNI L, Tyekucheva S, Hilbers FS, Ignatiadis M, et al
    Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
    Eur J Cancer. 2022;164:39-51.
    PubMed     Abstract available

    January 2022
  68. VAN DER PLAS-KRIJGSMAN WG, Morgan JL, de Glas NA, de Boer AZ, et al
    Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands - A comparison of two national prospective longitudinal multi-centre cohort studies.
    Eur J Cancer. 2022;163:189-199.
    PubMed     Abstract available

  69. KARSTEN MM, Roehle R, Albers S, Pross T, et al
    Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients.
    Eur J Cancer. 2022;163:128-139.
    PubMed     Abstract available

  70. TARANTINO P, Gandini S, Nicolo E, Trillo P, et al
    Evolution of low HER2 expression between early and advanced-stage breast cancer.
    Eur J Cancer. 2022;163:35-43.
    PubMed     Abstract available

  71. UGALDE-MORALES E, Grassmann F, Humphreys K, Li J, et al
    Interval breast cancer is associated with interferon immune response.
    Eur J Cancer. 2022;162:194-205.
    PubMed     Abstract available

    December 2021
  72. IWAMA E, Zenke Y, Sugawara S, Daga H, et al
    Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Eur J Cancer. 2021;162:99-106.
    PubMed     Abstract available

  73. PEUKER CA, Yaghobramzi S, Grunert C, Keilholz L, et al
    Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.
    Eur J Cancer. 2021;162:45-55.
    PubMed     Abstract available

  74. ALBANELL J, Martinez MT, Ramos M, O'Connor M, et al
    Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
    Eur J Cancer. 2021;161:26-37.
    PubMed     Abstract available

  75. JUAN Z, Chen J, Ding B, Yongping L, et al
    Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial.
    Eur J Cancer. 2021;161:10-22.
    PubMed     Abstract available

  76. GOLATTA M, Pfob A, Busch C, Bruckner T, et al
    The potential of combined shear wave and strain elastography to reduce unnecessary biopsies in breast cancer diagnostics - An international, multicentre trial.
    Eur J Cancer. 2021;161:1-9.
    PubMed     Abstract available

    November 2021
  77. PATSOURIS A, Diop K, Tredan O, Nenciu D, et al
    Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
    Eur J Cancer. 2021;159:283-295.
    PubMed     Abstract available

  78. CORTI C, Giachetti PPMB, Eggermont AMM, Delaloge S, et al
    Therapeutic vaccines for breast cancer: Has the time finally come?
    Eur J Cancer. 2021 Nov 22. pii: S0959-8049(21)01185.
    PubMed     Abstract available

  79. SCHNEEWEISS A, Michel LL, Mobus V, Tesch H, et al
    Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast
    Eur J Cancer. 2021 Nov 17. pii: S0959-8049(21)01164.
    PubMed     Abstract available

  80. HANNOUN-LEVI JM, Gutierrez C, Polgar C, Strnad V, et al
    Letter comments on: The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy.
    Eur J Cancer. 2021;159:224-226.

  81. VICIER C, Sfumato P, Isambert N, Dalenc F, et al
    TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
    Eur J Cancer. 2021;159:205-214.
    PubMed     Abstract available

    October 2021
  82. GAILLARD T, Carton M, Mailliez A, Desmoulins I, et al
    De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.
    Eur J Cancer. 2021;158:181-188.
    PubMed     Abstract available

  83. CAMPONE M, Bachelot T, Treilleux I, Pistilli B, et al
    A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial).
    Eur J Cancer. 2021;158:169-180.
    PubMed     Abstract available

  84. GARREFFA E, Hamad A, O'Sullivan CC, Hazim AZ, et al
    Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care.
    Eur J Cancer. 2021;159:38-51.
    PubMed     Abstract available

    September 2021
  85. HAN MG, Jang BS, Kang MH, Na D, et al
    PI3Kgammadelta inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Eur J Cancer. 2021;157:450-463.
    PubMed     Abstract available

  86. DAVEY MG, Richard V, Lowery AJ, Kerin MJ, et al
    OncotypeDX(c) Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.
    Eur J Cancer. 2021;154:209-216.
    PubMed     Abstract available

  87. GUARNERI V, Giorgi CA, Cinieri S, Bengala C, et al
    Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
    Eur J Cancer. 2021;154:21-29.
    PubMed     Abstract available

  88. HEIN A, Hartkopf AD, Emons J, Lux MP, et al
    Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.
    Eur J Cancer. 2021;155:1-12.
    PubMed     Abstract available

    May 2021
  89. SAESEN R, Lacombe D, Huys I
    Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer.
    Eur J Cancer. 2021;151:221-232.
    PubMed     Abstract available

  90. MORENO-ASPITIA A, Holmes EM, Jackisch C, de Azambuja E, et al
    Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
    Eur J Cancer. 2021;148:287-296.
    PubMed     Abstract available

  91. CAMPANALE A, Di Napoli A, Ventimiglia M, Pileri S, et al
    Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients.
    Eur J Cancer. 2021;148:277-286.
    PubMed     Abstract available

  92. VOS H, Lambein K, Wildiers H, Punie K, et al
    Immune-related adverse events after a single dose of pembrolizumab.
    Eur J Cancer. 2021;148:92-94.

    March 2021
  93. PUJOL P, Barberis M, Beer P, Friedman E, et al
    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Eur J Cancer. 2021;146:30-47.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.